Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06032195

Study of Organ Perfusion in Heart Transplantation in Children

The goal of this prospective randomized single blind multicenter phase II study is to compare organ perfusion with Custodiol-N and Custodiol in heart transplantation in children of all ages (birth to <18 years) being listed on the waiting list for heart transplantation. The main question it aims to answer is:

to compare the safety of Custodiol-N in heart transplantation in children in comparison to its precursor product Custodiol.

Participants will receive either a heart to be transplanted, either perfused with Custodiol-N or Custodiol to Researchers will compare the two solutions to see if the new solution Custodiol-N is safe in heart transplantation in children.

Recruiting

Interested in participating?

Request Info

Key information

Age range

24 hour–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Deutsches Herzzentrum der Charité, Berlin, Germany

Loading trial locations.

About this study

Orthotopic Heart transplantation (or cardiac transplantation) is a procedure performed in patients with end stage heart failure when other treatments have failed.

The surgical procedures for orthotopic heart transplantation are essentially the same in adult and paediatric patients . Due to anatomical variants in congenital heart disease the procurement procedure may be modified with regard to the extent of the Vena cava superior and the great vessels. In implantation most frequently the bicaval technique is used but the biatrial technique which is leaving the back wall of both atria in situ may also be employed.

A main difference between adult and paediatric heart transplantation (HTx) are the indications for transplantation: In adults the majority of patients undergo HTx as treatment of end stage heart failure due to cardiomyopathy or severe coronary artery disease when other treatments have failed. Infants younger than one year of age congenital heart disease (CHD) is the most common diagnosis representing more than every second case followed by dilated cardiomyopathy (DCM) in more than one third of cases. In older patients DCM is the most frequent underlying diagnosis. CHD may include patients who have undergone corrective surgery and in whom myocardial dysfunction develops later .

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from birth to less than18 years
  • Recipients awaiting their first transplant
  • Ability of the patients and/ or their legal guardians to understand character and individual consequences of the clinical trial
  • written informed consent of the patients and/ or their legal guardians (must be available before enrolment in the study)
  • Patient listed on the waiting list for heart transplantation

Exclusion criteria

  • Patients who have participated within 30 days or are still participating in any other interventional studies
  • history of severe organic disease other than concerning the heart
  • history/demonstration of HIV antibodies or AIDS
  • multiorgan transplantation
  • machine-perfused organ
  • the explantation team is affiliated to another clinic than transplantation team
  • Failing Fontan patients
  • Patients who have been incarcerated or involuntarily institutionalized by court order or by the authorities
  • Pregnancy and lactation

Treatment and study plan

Custodiol-N

Drug

heart will preserved in and will be treated with Custodiol-N solution

Other names: Solution for organ preservation in transplantation

Custodiol

Drug

heart will preserved in and will be treated with Custodiol solution

Other names: Solution for organ preservation in transplantation

Primary outcomes

  1. adverse event reporting

    Time frame: up to 3 months

    Safety assessment

Secondary outcomes

  1. heart rate

    Time frame: up to day 7 after release of the aortic cross clamp

    vital parameters

  2. blood pressure (systolic (SBP) and diastolic (DBP))

    Time frame: up to day 7 after release of the aortic cross clamp

    vital parameters

  3. body temperature

    Time frame: up to day 7 after release of the aortic cross clamp

    vital parameters

  4. concentration of cardiac troponin

    Time frame: up to day 7 after release of the aortic cross clamp

    laboratory tests

  5. concentration of creatinine kinase (CK-MB)

    Time frame: up to day 7 after release of the aortic cross clamp

    laboratory tests

  6. (SBP (systolic blood pressure), DBP (diastolic blood pressure))

    Time frame: from termination of cardiopulmonary bypass until transfer to intensive care unit

    Haemodynamics

  7. Heart Rhythm (HR)

    Time frame: from termination of cardiopulmonary bypass until transfer to intensive care unit

    Haemodynamics

  8. Pulmonary artery pressure (PAP (if available))

    Time frame: from termination of cardiopulmonary bypass until transfer to intensive care unit

    Haemodynamics

  9. Cerebrovascular resistance (CVP (if available))

    Time frame: from termination of cardiopulmonary bypass until transfer to intensive care unit

    Haemodynamics

  10. Death

    Time frame: up to 12 months

    survival

  11. function of transplanted organ (heart)

    Time frame: up to 12 months

    Graft survival

  12. Readmission to intensive care unit (ICU)

    Time frame: up to 12 months

    return to intensive care unit

  13. Length of ICU stays

    Time frame: up to 12 months

    duration of stay in intensive care unit

  14. Catecholamine requirement

    Time frame: up to day 7

    (yes/no)

  15. Antihypertensives intake

    Time frame: up to 12 months

    (yes/no)

  16. Milrinone support

    Time frame: up to day 7

    (yes/no)

  17. Need for pacemaker therapy

    Time frame: up to day 7

    (yes/no)

  18. Left and right ventricular assist device (LVAD, RVAD)

    Time frame: up to 12 months

    Device therapy (each yes/no)

  19. Extracorporeal membrane oxygenation (ECMO)

    Time frame: up to 12 months

    Device therapy (each yes/no)

  20. Biventricular assist Device (BIVAD) or percutaneous LVAD

    Time frame: up to 12 months

    Device therapy (each yes/no)

  21. Ejection fraction

    Time frame: up to day 7

    Echocardiographic markers of function and rejection

  22. enddiastolic and endsystolic ventricle

    Time frame: up to day 7

    Echocardiographic markers of function and rejection

  23. Cardiac arrhythmias

    Time frame: up to day 7

    occurrence, severity, type

Study contacts

Contact information is provided by the study sponsor or research team.

Kathleen Steyrer

CONTACT

[email protected]

+49-6221-56 ext. 36411

Roman Petrov, Dr.

CONTACT

[email protected]

+ 49-6251-1083 ext. -0

Sponsors and collaborators

Lead sponsor

Dr. F. Köhler Chemie GmbH

Industry

Registry information

Official study title

A Prospective Randomized Single Blind Multicenter Phase II Study of Organ Perfusion With Custodiol-N Compared With Custodiol in Heart Transplantation in Children

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Sep 11, 2023
Registry last updated
Jan 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.